Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of Frontline Therapy With Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD)

NCT06040320 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.

NCT NCT06040320
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06040320 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of Frontline Therapy With Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD)
Lead sponsor
Washington University School of Medicine
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
October 4, 2023
Completion date
May 31, 2032
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

post-transplant lymphoproliferative disorder